IP/C/INF/2  
 
26 September 2023  
(23-6409) Page: 1/10 
Council for Trade -Related Aspects of  
Intellectual Property Rights  Original: English  
 
COUNCIL FOR TRIPS  
 
PARAGRAPH 8 OF THE MINISTERIAL DECISION ON THE TRIPS AGREEMENT  
 
INFORMAL THEMATIC SESSION FOR EXTERNAL STAKEHOLDER INPUT  
 
Geneva, 28 September 2023 - Centre William Rappard, Room W  
8.45 a.m. – 5.30 p.m.  
 
Revised Programme  
8h45 – 9h00 
 Opening  
H.E. Ambassador Pimchanok Pitfield  – Chair of the Council for TRIPS  
 
9h00 – 10h00  Data collection and analysis on vaccines, therapeutics and diagnostics  
[Ms Paulina Rivas Calder ón, Market Research Officer, United Nations Children 's 
Fund (UNICEF) , Operator of the COVID -19 Market Dashboard ] 
Mr Rasmus Bech Hansen , Co-founder & CEO at Airfinity Ltd.  
Dr Emma Hannay , Chief Access Officer, FIND, Global Alliance for Innovation in 
Diagnosti cs, co -convener of the ACT Accelerator Diagnostics Pillar  
 
Questions & Answers  (15 minutes)  
10h00 – 11h30  
 
 
 
 Intergovernmental organizations and international initiatives  
Prof. John Reeder , Director, Research for Health Department  and Director TDR , 
World Health Organization (WHO)  
Ms Erika Dueñas Loayza , Technical Officer, Department of Essential Medicines and 
Health Products,  World Health Organization (WHO)  
Mr Edward Kwakwa , Assistant Director General, Global Challenges and Partner ships 
Sector, World Intellectual Property Organization (WIPO)  
Ms Amy Dietterich , Director, Global Challenges Division, World Intellectual Property 
Organization (WIPO)  
Mr Nirmalya Syam , Senior Program Officer , Health, Intellectual Property and 
Biodiversity Programme, South Centre  
Mr Charles Gore , Executive Director , Medicines Patent Pool (MPP)  
 
Questions & Answers  (15 minutes)  
 
  IP/C/INF/2  
 
- 2 - 
 
 
Revised Programme  
11h30 – 13h00  
 
 Civil Society Organizations  
Mr Tahir Amin , CEO, Initiative for Medicines, Access & Knowledge (I -MAK), United 
States of America  
Dr Ellen 't Hoen , Director, Medicines Law and Policy , The Netherlands  
Ms Sangeeta Shashikant , Third World Network , Malaysia  
Mr James Packard Love , Director , Knowledge Ecology International , United States 
of America  
Ms Fatima Hassan , Director/Founder, Health Justice Initiative, South Africa  
Ms Jennifer Brant , Director, Innovation Council , Switzerland  
 
Questions & Answers  (15 minutes)  
13h00 – 14h30 Lunch  
14h30 – 16h30 
 
 
 
 
 
 
 
 Business   
Dr Julia Spencer , Associate Vice President , Global Multilateral Engagement  & 
Strategic Alliances, MSD 
Ms Els ie Soto , VP Supply Chain, Emerging Markets, Pfizer  Global Supply  
Mr Cheik Tidiane Diagne , Head of Operations, DIA TROPIX , Institut Pasteur  de 
Dakar, Senegal  
Mr Osman Khalid Waheed , CEO, Ferozsons Laboratories Ltd., Pakistan  
Dr Morena Makhoana , CEO, Bio vac, South Africa  
Mr Alejandro G ómez L ópez, Health Secretary of the District of Bogota, Speaker of 
BogotáBio, Colombian Public Enterprise for the local productio n of vaccines  
 
Questions & Answers  (30 minutes)  
16h30 – 17h15 Academics   
Dr Daria Kim , Max Planck Institute for Innovation and Competition , Munich, 
Germany  
Prof. Dr Yangmu Huang , Deputy Director, Department of Global Health, Research 
Professor, Beijing  University, China  
Prof. William Fisher , Wilmer Hale Professor of Intellectual Property Law, Harvard 
University  
 
Questions & Answers  (15 minutes)  
17h15 – 17h30    Closing  
H.E. Ambassador Pimchanok Pitfield  – Chair of the Council for TRIPS  
 
  IP/C/INF/2  
 
- 3 - 
 
COUNCIL FOR TRIPS  
 
PARAGRAPH 8 OF THE MINISTERIAL DECISION ON THE TRIPS AGREEMENT  
 
INFORMAL THEMATIC SESSION FOR EXTERNAL STAKEHOLDER INPUT  
 
Geneva, 28 September 2023 - Centre Willia m Rappard, Room W  
 8.45 a.m. – 5.30 p.m.  
BIOGRAPHIES OF SPEAKERS  
Data collection and analysis on vaccines, therapeutics and diagnostics  
Mr Rasmus Bech Hansen , CEO, Airfinity, Predictive Health Intelligence and Data Analytics  
Rasmus is a globally recognised global health security expert 
and data entrepreneur. The first part of his career he worked 
as strategist and partner in various boutique advisory firms 
working for governments, UN entities, and corporates, in 
particular pharmaceuticals. He also  had a regular column in a 
national newspaper and wrote a book on innovation.  
He founded Airfinity as a result of having personally 
experienced how better health data can or could have saved 
lives. For the last 8 years, he has, as CEO, spearheaded the 
comp any's development and driven its high impact predictive 
analysis.  
 
He is often quoted in leading media outlets such as Financial Times, Bloomberg and CNN and is a 
regular key -note speaker at events such as the Rhodes Summit and the FT Pharma and Biotech 
Summit. He holds a B.Sc. in Political Science, a MPA from Harvard University and is a recipient of 
the Crown Prince Frederic award for excellent scholarship. He lives in London with his wife and two 
sons.  
 
 
Dr Emma Hannay, Chief Access Officer, FIND, Global  Alliance for Innovation in Diagnostics  
 
Emma is FIND 's Chief Access Officer and recently led the ACT -Accelerator 
Diagnostics Partnership on behalf of FIND and The Global Fund. She is a 
public health doctor with a focus on global health strategy and deliv ery.  Her 
work has been centred at a global level on organizational strategy in global 
health, and at a country level in implementing health systems reforms in 
complex operating environments.  
 
In her previous role as Head of Health at Acasus, she was part of the team 
leading the Pakistan Health Reforms Roadmaps, which improved primary 
care for more than 150 million people, and the DRC 's Mashako Plan to 
increase immunization coverage for children. Prior to joining Acasus she was 
the manager of the Market Dyn amics Team at Unitaid in Geneva, and an 
Engagement Manager for McKinsey & Company based out of Dubai and 
Washington, DC. She holds a medical degree from the University of Auckland, New Zealand and a 
Master of Public Health from Harvard University.  
  
IP/C/INF/2  
 
- 4 - 
 
Intergovernmental organizations and international initiatives  
 
Prof. John Reeder , Director Research for Health Department and Director of the 
UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases 
(TDR), World Health Organization, (WHO)  
 
Professor John Reeder is Director of TDR, the Special Programme for 
Research and Training in Tropical Diseases (since 2012) and Director of 
the WHO Research for Health Department (since 2019). In these positions 
he has responsibility for co -ordina ting an effective, strategic and well -
harmonized research effort across the WHO.   
Before joining WHO, he was most recently Co -Director of the Centre for 
Population Health at the Burnet Institute, Melbourne, Australia. Before 
this, he was Director of the Pa pua New Guinea Institute of Medical 
Research, where he worked on translating scientific findings from the field 
into policy for improved health.  
John began his career in medical microbiology laboratories in the United 
Kingdom and then moved to health trai ning as a development volunteer 
in the Highlands of Papua New Guinea, before joining the world -renowned malaria research team at 
the Walter and Eliza Hall Institute.  
A naturalized Australian, born and educated in England, he received his PhD in medical microbiology 
at the University of Manchester. He has published around 200 scientific papers, that span basic 
laboratory research to large community -based field studies . Among a number of honours, Professor 
Reeder received the 2020 Mitchell Humanita rian Award for his contribution to end the debilitating 
disease onchocerciasis.  
 
 
Ms Erika Dueñas Loayza , Technical Officer, Department of Essential Medicines and Health 
Products, World Health Organization (WHO)  
Erika Dueñas  leads the Intellectual Propert y Unit at WHO HQ/Access to 
Medicines and Health Products Division providing technical advice on 
issues related to innovation, access to health technologies, and 
Intellectual Property (IP). She also supports activities to build and 
strengthen national and r egional capacities in the intersections between 
public health, trade and IP. Erika worked at the Medicines Patent Pool 
and has more than 20 years of experience in the field of access to 
medicines, innovation and IP. As a career diplomat, she worked many 
years for the Bolivian government. After her diplomatic mission at the 
Embassy in Washington as Chargée d 'Affaires, she was Vice -Minister at 
the Ministry of Foreign Affairs in Bolivia. Erika holds a Master 's degree in 
International Law and Economics (LLM) fr om the World Trade Institute/Universities of Bern, Fribourg 
& Neuchâtel – Bern, Switzerland . 
 
 
Mr Edward Kwakwa , Assistant Director General, Global Challenges and Partnerships Sector, World 
Intellectual Property Organization (WHO)  
 
Edward Kwakwa  is Assistant Director General, Global Challenges and 
Partnerships Sector, World Intellectual Property Organization (WIPO) in 
Geneva. He served as General Counsel at WIPO from 2004 until 
September 2016. Kwakwa holds an LL.B. degree from the University of 
Ghana, an LL.M. from Queen 's University in Canada, and an LL.M. and a 
J.S.D. from Yale Law School in the U.S.A.  
Before joining WIPO, Kwakwa practiced with the law firm of O 'Melveny 
and Myers in Washington, D.C., worked as International Legal Adviser at 
the Commission on Global Governance in Geneva, as Senior Legal Adviser 
at the Office of the United Nations High Commissioner for Refugees 
(UNHCR), and as Legal Affairs Officer at the World Trade Organization 
(WTO) . 
 
IP/C/INF/2  
 
- 5 - 
 
Ms Amy Dietterich , Director, Global Challen ges Division, World Intellectual Property Organization 
(WIPO)  
 
Marion "Amy" Dietterich is the Director of the Global Challenges Division at the World Intellectual 
Property Organization (WIPO). In this role, she covers Intellectual 
Property (IP) -related gl obal policy issues in the areas of Global Health, 
Climate Change, and Food Security.  
 
Amy has twenty years of experience in the fields of public health, water 
& sanitation, and governance, spanning community -based organizations, 
international NGOs, global health partnerships, and United Nations 
institutions. Prior to joining WIPO in 2018, she worked with the 
International Federation of Red Cross and Red Crescent Societies (IFRC) 
to ensure stronger community engagement in health systems governance 
and service delivery, and with the Parliamentary Network on the World 
Bank and IMF to support parliamentary oversight of development 
cooperation and financing.  
 
Ms. Dietterich earned her academic qualifications in Public Health, Biology, and French from the 
London School of Hygiene and Tropical Medicine (LSHTM) and Bucknell University in 2005 and 2000 
respectively.  
 
 
Mr Nirmalya Syam , Senior Program Officer, The South Centre  
 
Mr Syam has more than 10 years ' experience on issues related to IPRs 
and access to m edicines. He holds a bachelor 's degree in law (LL.B) from 
the University of Calcutta and a master 's degree (M.Phil.) in international 
law from Jawaharlal Nehru University, New Delhi.  
 
 
 
 
 
 
 
 
 
 
 
Mr Charles Gore , Executive Director, Medicines Patent Pool (MPP ) 
 
Charles Gore is the Executive Director of the Medicines Patent Pool (MPP). 
Following a career in patient representation and public health advocacy, he 
took up the post in July 2018 to guide MPP in its expansion into new areas 
covered by the WH O Essential Medicines List.    
  
He was diagnosed with hepatitis C in 1995 and cirrhosis in 1998. In 2000 
he set up The Hepatitis C Trust in the UK which he ran for 18 years. In 
2002 he was treated and cured of the virus.  He helped create the European 
Liver Patients Association and was its first President in 2004. In 2007 he 
established the World Hepatitis Alliance and was President until December 
2017. As a result of advocacy by the Alliance, WHO adopted successive  
viral hepatitis resolutions in 2010, 2014 and 2016, culminating in endorsement of the goal of 
eliminating hepatitis B and C by 2030.  
  
Charles has sat on a number of national and international advisory bodies including the WHO 
Director -General’s HIV and Hepatitis STAC, various WHO regional ST ACs and up till 2019 was a 
member of all the WHO guideline development groups on testing and treating viral hepatitis.   
 
. 
  
IP/C/INF/2  
 
- 6 - 
 
Civil Society Organizations  
 
Mr Tahir Amin , Initiative for Medicines, Access & Knowledge ( "I-MAK") 
 
Tahir Amin, LL.B., Dip. LP., is a founder and executive director of the 
Initiative for Medicines, Access & Knowledge (I -MAK), a nonprofit 
organisation working to address structural inequities in how medicines 
are developed and distributed. He has over 25 years of ex perience in 
intellectual property (IP) law, during which he has practised with two of 
the leading IP law firms in the United Kingdom and served as IP Counsel 
for multinational corporations. His work focuses on re -shaping IP laws 
and the related global poli tical economy to better serve the public 
interest, by changing the structural power dynamics that allow health 
and economic inequities to persist.  
 
He is a former Harvard Medical School Fellow in the Department of 
Global Health & Social Medicine. Amin has served as legal advisor/consultant to many international 
groups, including the European Patent Office, UNITAID and World Health Organization, and 
has testified before the U.S. Congr ess on intellectual property and unsustainable drug prices.  
 
 
Dr Ellen 't Hoen , Director, Medicines Law and Policy  
 
Ellen 't Hoen (1960) is the director of Medicines Law & 
Policy  (ML&P) , a group of legal and policy experts offering 
advice to international organizations, NGOs and 
governments. ML&P regularly publishes briefing 
documents and commentaries on legal and policy 
developments in the field of medicines. ML&P also 
maintains a public database of the use of TRIPS 
flexibilities for public health purposes . She is the founder 
and former executive director of the Medicines Patent 
Pool. She is also a Global Health Law Fellow at the law 
faculty of the University of Groningen.  
 
She has published widely and is the author of several b ooks. In 2017 she received the Prix Prescrire  
for her book  "Private Patents and Public Health: Changing intellectual property rules for public 
health. "  In 2020, she was appointed Officer of the Order of Oranje -Nassau, a Dutch royal  award 
given in recognition of her work on access to medicines. She has a master 's degree in law from the 
University of Amsterdam and a PhD from the University of Groningen.  
 
 
Ms Sangeeta Shashikant , Third World Network, Malaysia  
 
Sangeeta Shashikant is the coordinator of Third World Network 's 
Development and IP programme. She has Bachelor of Laws (University of 
Malaya); Masters Degree in Public International Law (University College 
London), and has practiced as an advocate and solicitor wit h the Malaysian 
Bar. She has 19 years of research and advocacy experience in intellectual 
property and public policy matters in particular access to medicines. She 
has collaborated with regional and international organizations and advised 
governments on in tellectual property and access to medicines. She has 
authored and contributed towards numerous publications including 
"Negotiating a 'Development Agenda ' for the World Intellectual Property 
Organisation "; "Intellectual Property and Technology Transfer Issu es in the Context of Climate 
Change "; "The African Regional Intellectual Property Organization (ARIPO) Protocol on Patents: 
Implications for Access to Medicines " and the "Pandemic Preparedness: Creating a Fair and Equitable 
Influenza Virus and Benefit Shar ing System ".  
 
 
 
 
IP/C/INF/2  
 
- 7 - 
 
Mr James Love , Director, Knowledge Ecology International (KEI), United States of America  
 
James Love is Director of Knowledge Ecology International. His training 
is in economics and finance, and work focuses on the production, 
management and access to knowledge resources, as well as aspects of 
competition policy.  
 
The current focus is on the financing of research and development, 
intellectual property rights, prices for and access to new drugs, vaccines 
and other medical technologies, as well as related topics for other 
knowledge goods, including data, software, other information protected 
by copyright or related rights, and proposals to expand the production of knowledge as a public 
good. James Love holds a Masters of Pub lic Administration from Harvard University 's Kennedy School 
of Government and a Masters in Public Affairs from Princeton 's Woodrow Wilson School of Public and 
International Affairs.   
 
 
Ms Fatima Hassan , Health Justice Initiative, South Africa  
 
Fatima Hass an is a human rights lawyer and social justice activist and the 
founder of the HJI.  She is the recipient of the 2022 Calgary Peace Prize and 
is a 2023 Echoing Green Fellow. She has dedicated her professional life to 
defending and promoting human rights in South Africa, especially in the field 
of HIV/AIDS. She has worked as a Ministerial Advisor, and in philanthropy 
as well as the not -for-profit sector.  
 
She has served on several NFP boards and is the recipient of several awards, 
and often writes for local a nd international media publications. She is 
currently a Board Member of Global Witness and serves on the Advisory 
Group for Resolve to Save Lives.   
 
 
Ms Jennifer Brant , Director, Innovation Council, Switzerland  
 
Jennifer Brant runs a consulting business called Innovation Insights, based 
in Geneva, Switzerland. She works with companies, NGOs, governments, 
and international organizations on policy issues related to intellectual 
property (IP) and innovation, technology transfer, international trade,  and 
public health. She is committed to gender parity, leading global advocacy 
campaigns to tackle IP diversity gaps and serving as member of the 
International Gender Champion network.  
 
As part of her consulting work, Jen leads a cross -sectoral innovators ' group 
called Innovation Council. This global organization connects policymakers 
to organizations that are bringing technology solutions to society. Jennifer 
is trained in international law, development, and economics. She has 
authored and co -authored many  reports and articles, including 
Unprecedented (2022), which analyses  the role of intellectual property in the COVID -19 innovation 
response, and Biomanufacturing Resilience  (2023), which endorses action by governments and 
companies to reinforce biologics s upply chains.  
  
IP/C/INF/2  
 
- 8 - 
 
Business  
 
Dr Julia Spencer, AVP, Global Multilateral Engagement, Strategic Alliances, and International 
Relations, MerkSD  
 
Julia Spencer serves as the lead for MSD 's engagement with key global 
multilateral organizations, embassies, consulates, and missions in 
Washington, DC, New York, and Geneva, and is based in Geneva, 
Switzerland. She is also the focal point for and coordinates the company 's 
participation in international industry trade associations and business 
groups a nd directs the multilateral and strategic alliance policy agenda 
focused on UN and international health, trade, and innovation 
organizations; G7/G20 and other global government alliances; health 
security organizations, and economic and financing institutio ns. 
Prior to taking on this role, Julia served for 5 years as the Associate Vice 
President, Global Vaccines Public Policy, Partnerships, and Government 
Affairs, during which time she led global policy and advocacy efforts to 
expand and sustain access to MS D's vaccines and to strengthen the 
immunization systems delivering our products. Julia also served as the Chair 
of the International Federation of Pharmaceutical Manufacturers and Associations ' (IFPMA) Vaccine 
Committee from 2021 -2022.  
 
Prior to joining Me rck, Julia served for 15 years as a senior health official in the US Department of 
Health and Human Services (HHS). Her tenure at HHS included service as the Science Policy Director 
within the HHS Secretary 's policy, planning, and evaluation office (ASPE) where she was responsible 
for policy analysis, coordination, planning, and legislative development focused on the HHS science 
agencies – Centers for Disease Control and Prevention, Food & Drug Administration , National 
Institutes of Health, and Office of the Assistant Secretary for Preparedness and Response.  
During the decade she worked in ASPE, she led the creation of two 5 -year HHS Strategic Plans, the 
first HHS Global Health Strategy and the Health System Measurement Project; developed a new 
HHS-wide evaluation capacity development initiative; and served on assignment in the US CDC 
Rwanda Office.  
 
Prior to joining ASPE, Julia spent six years working on tobacco policy and substance abuse prevention 
efforts w ith HHS 's Substance Abuse and Mental Health Services Administration. Julia holds a Doctor 
of Philosophy degree in public health, Master of Science in public health, and Bachelor 's degrees in 
psychology and health education.  
 
 
Ms Elsie Soto, VP Supply Chain , Emerging Markets & China, Pfizer Global Supply  
 
Elsie initiated her career in Pfizer Puerto Rico in 1993. Elsie assumed 
positions of increased responsibility at the Vega Baja and Fajardo sites, and 
then internationally in Spain, Korea, the US and Hong K ong. Elsie was 
honoured  in 2011 with the National Hispanics Corporate Achievers Award 
for her career accomplishments as a corporate leader at Pfizer.  In 2013, 
Elsie was appointed Vice President Product Portfolio Management (PPM) for 
Pfizer 's Established Bu siness.  
 
In 2016 she assumed the role of VP PPM for the Innovative Business. In 
2019 she was appointed to her current role as VP Supply Chain Emerging 
Markets and China overseeing the supply strategic aspects and commercial 
interface of those areas. During  the Pandemic, Elsie co -led Pfizer 's COVID 
Manufacturing taskforce. Elsie is also currently leading the Manufacturing 
& Supply Chain activities related to the Accord for Healthier World.  Elsie holds a bachelor 's degree 
in Industrial Engineering from the Un iversity of Puerto Rico at Mayaguez.  She brings 30 years of 
site, market, and cent re experience in the areas of Procurement, Product Transfers, New Product 
Launches, Site Production Planning, Logistics, PGS Market Leadership, Business Development, 
Portfol io Strategy and Supply Chain Management in both Established and Innovative Businesses to 
her role.  
 
 
IP/C/INF/2  
 
- 9 - 
 
 
Mr Cheik Tidiane Diagne , Head of Operations, DIATROPIX, Institute Pasteur, Dakar, Senegal  
 
Dr. Cheikh Tidiane Diagne  trained at the Centre National de la Recherche 
Scientifique and at  the University of Toulouse (France) where he graduated 
in 2013 with a PhD in Structural and  Functional Biology. His PhD research 
was focused on the dynamic analysis and assembly of  site-specific DNA 
recombination machineries using single molecule techniques. From 2014 to  
2016, he worked at the Electronics Department (LETI) of the French 
Commission for Atomic  Energy and Alternative Energies (CEA) in Grenoble 
(France) as a postdoctoral researcher.  There, his research efforts were 
focused on bio -inspired technologies for molecular  electronics.  
 
Dr. Diagne joined the virology department and the WHO collaborating for arboviruses an d 
haemorrhagic fever viruses of the Pasteur Ins titute of Dakar in Senegal in 2016. His primary  interests 
were centred on innovation for Global Health, particularly on the development and  evaluation of 
point-of-care diagnostic tools, digital health for biosample transportation and  banking  and rapid 
extraction method for nucleic acid amplification. Since March 2020, he has  been leading  the 
DIATROPIX laboratory, a social venture founded by the Institut Pasteur de  Dakar (Senegal), the  
Merieux Foundation (France), the Foundation for Innovative New  Diagnostic  (Geneva) and the 
Institut de Recherche et de Développement (France). DIATROPIX  focuses on local manufacturing of 
rapid diagnostic tests for neglected and epidemic diseases  in Africa.  
 
 
Mr Osman Khalid Waheed , CEO, Ferozsons Laboratories Ltd., Pakistan  
 
Osman Khalid Waheed joined Ferozsons Laboratories Limited, a publicly listed 
pharmaceutical company in 1993 after obtaining his undergraduate degree 
from Harvard. During his tenure as CEO since 1998, the company has forged 
alliances with international part ners including the Boston Scientific 
Corporation and Gilead Sciences Inc. to expand access in disease areas 
including heart disease, viral hepatitis, HIV and Covid -19. In 2019, Ferozsons 
became one of 9 international producers selected to manufacture and  supply 
its therapeutic remdesivir to 127 low and middle -income countries under a 
voluntary license from Gilead. Mr. Waheed serves as a trustee of LUMS, 
Pakistan 's premier multi -disciplinary university, and was the founding 
chairman of the Lahore Biennale F oundation, a non -profit dedicated to public 
art.  
 
 
Dr Morena Makhoana , CEO, Bio vac, South Africa  
 
Dr Morena Makhoana joined Biovac in 2004 and holds the role of Chief 
Executive Officer. He is a member of the Board and the Biovac Executive 
team.  Prior to his CEO role at Biovac he held the role of Deputy CEO and prior 
to that of Medical Affairs Director for Biovac.  
 
His mandate is to realise the objective of building vaccine manufacturing 
capacity in Southern Africa. During his tenure Biovac has attracted t hree 
successful technology transfers with global pharmaceutical companies such 
as Sanofi and Pfizer that has allowed the company to grow its staff 
complement from 24 to over 400. Biovac’s next phase is to enter  strengthen 
its product development as well a s its drug substance capability in order for 
Biovac and Africa to have end to end manufacture.  
 
Morena is a medical graduate from the University of Cape Town (UCT) in South Africa. He has 
participated in numerous executive and business courses at both Harvard and Stanford Universities.  
 
 
 
 
 
IP/C/INF/2  
 
- 10 - 
 
Mr Alejandro Gómez López , Health Secretary of the District of Bogota, Speaker 
of BogotáBio, Colombian Public Enterprise for the local production of vaccines  
 
Medical Doctor. Specialist in Health Auditing and Finance. Master in Political and 
International Studies. He has more than 20 years of experience in the hea lth 
sector, holding positions in all areas: delivery, insurance and government. He 
was National Director of Nutrition for the Colombian Institute of Family Welfare 
(ICBF) and Director of Public Health for the Mayor 's Office of Medellín.  
 
 
 
Academics  
 
Dr Daria Kim , Max Planck Institute for Innovation and Competition  
 
Daria Kim is a Senior Research Fellow at the Max Planck Institute for 
Competition and Innovation (Munich). She holds MA (Indiana University of 
Pennsylvania), LLM (Munich Intellectual Property Law Center), and Dr iur 
(University of Augsburg) degrees.  
Her r esearch focuses on topics at the intersection of law, technology, and 
society, which include intellectual property law, governance frameworks for 
medical and genomic research, marketing authorisation regulations, and access 
to data within the context of th e data economy. 
https://www.ip.mpg.de/en/persons/kim -daria.html  
 
 
Prof. Dr Yangmu Huang , Deputy Director, Department of Global Health, Research Professor, 
Beijing University, China  
 
Yangmu Huang is deputy director, research professor and doctoral supervisor 
in the Department of Global Health, School of Public Health, Peking University. 
Her research focuses on global health governance, R&D and public health, an d 
health emergency, which mainly aims at the vulnerable population. She has 
hosted and participated in tens of national and international research projects 
supported by National Natural Science Foundation of China, World Health 
Organization (WHO), etc. She  has published over 60 articles in peer reviewed 
journals, such as the Lancet. As the senior consultant of the China 's 
Delegation, she has been invited to attend the World Health Assemble, WHO 
Executive Board annually. She has also provided consultation fo r China 's 
national ministries and commissions, such as the National Health Commission, 
UN agencies, etc. Due to her contribution and achievements, she was awarded 
as Health Young Physician Leaders (ranked 1st in 2019) by the InterAcademy 
Partnership.  
 
Prof. William Fisher , William Fisher, Wilmer Hale Professor of Intellectual Property Law, Harvard 
University  
 
William Fisher  received his undergraduate degree (in American Studies) from 
Amherst College and his graduate degrees (J.D. and Ph.D. in the History of 
American Civilization) from Harvard University. Between 1982 and 1984, he 
served as a law clerk, first to Judge Harry T.  Edwards of the US Court of 
Appeals for the D.C. Circuit and then to Justice Thurgood Marshall of the US 
Supreme Court.  Since 1984, he has taught at Harvard Law School, where he 
is now the Wilmer Hale Professor of Intellectual Property Law.   In 2013, he 
created the CopyrightX online course, which is now offered annually to 
approximately 1000 students worldwide.  In 2011 he and Professor Ruth 
Okediji created a similar course on Patent Law and Global Public Health, which 
is now offered semiannually in collab oration with the World Intellectual 
Property Organization.   He is currently a director of Global Access in Action, a 
non-profit organization, based at Harvard Law School, whose primary mission is improving public 
health in low and middle -income countries.  
__________